The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 29, 2024

Filed:

Jan. 11, 2018
Applicant:

Naishuo Zhu, Shanghai, CN;

Inventors:

Naishuo Zhu, Shanghai, CN;

Changwu Hu, Shanghai, CN;

Assignee:

Other;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 7/08 (2006.01); A61K 38/00 (2006.01); C07K 14/00 (2006.01); G01N 33/532 (2006.01); G01N 33/68 (2006.01);
U.S. Cl.
CPC ...
C07K 14/001 (2013.01); C07K 7/08 (2013.01); G01N 33/532 (2013.01); G01N 33/6863 (2013.01); A61K 38/00 (2013.01); G01N 2333/525 (2013.01);
Abstract

Peptide with high binding affinity for tumor necrosis factor alpha (TNF-α). The peptide has an amino acid sequence of SEQ.ID.NO.1, or the peptide is a tandem or branched peptide with a single repeat or multiple repeats of SEQ.ID.NO.1 and SEQ.ID.NO.3 and has an amino acid sequence of SEQ.ID.NO.4. The peptide can bind to TNF-α with high affinity and can antagonize TNF-α function. When being directly injected to an animal, the peptide can significantly reduce the degree of inflammation of an animal body and improve the resistance of the animal body on an inflammatory damage. The peptide can be used for developing TNF-α antagonist drugs for treating various acute and chronic inflammatory damage, such as inflammatory, autoimmune and stress damage caused by physical, chemical and biological factors. Thus, the peptide has an extremely wide application prospect. Moreover, the peptide has a small molecular weight and low immunogenicity, and is easy to synthesize, thereby avoiding the side effects and disadvantages of traditional monoclonal antibody drug antagonists.


Find Patent Forward Citations

Zhu, Naishuo. (2024). High-affinity peptide for tumor necrosis factor alpha and application thereof (U.S. Patent No. 12129278). U.S. Patent and Trademark Office. https://idiyas.com/patent/badge/12129278

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Loading…